Baker Bros. Advisors LP Discloses Passive Stake in Sera Prognostics

TL;DR

**Baker Bros. Advisors LP just revealed a passive stake in Sera Prognostics, Inc. as of year-end 2023.**

AI Summary

Baker Bros. Advisors LP, a New York-based investment firm, filed an SC 13G on January 10, 2024, disclosing its ownership of Sera Prognostics, Inc. common stock as of December 31, 2023. This filing indicates that Baker Bros. Advisors LP holds a significant, but passive, stake in Sera Prognostics, Inc., a medical laboratories company. For investors, this matters because it signals a notable institutional investor's confidence in Sera Prognostics, Inc., potentially influencing market perception and future stock performance.

Why It Matters

This filing reveals a major institutional investor's position in Sera Prognostics, Inc., which can be seen as a vote of confidence and may attract other investors.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of a passive investment, indicating no immediate change in company control or strategy.

Analyst Insight

A smart investor would note Baker Bros. Advisors LP's position as a potential positive signal and research Sera Prognostics, Inc.'s fundamentals and recent performance to understand the rationale behind this institutional investment.

Key Players & Entities

• Baker Bros. Advisors LP (company) — the reporting person and investment firm
• Sera Prognostics, Inc. (company) — the subject company, a medical laboratories firm
• Felix J. Baker (person) — a group member of Baker Bros. Advisors (GP) LLC
• Julian C. Baker (person) — a group member of Baker Bros. Advisors (GP) LLC
• December 31, 2023 (date) — the date of the event requiring the filing
• January 10, 2024 (date) — the filing date of the SC 13G
• $0.0001 (dollar_amount) — par value per share of Sera Prognostics, Inc. Common Stock

Forward-Looking Statements

• Sera Prognostics, Inc. stock may experience increased investor interest due to Baker Bros. Advisors LP's disclosed stake. (Sera Prognostics, Inc.) — medium confidence, target: Q1 2024
• Baker Bros. Advisors LP will maintain a passive investment in Sera Prognostics, Inc. for the foreseeable future. (Baker Bros. Advisors LP) — high confidence, target: Q4 2024

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• tm242424d2_sc13g.htm (SC 13G) — 86KB
• tm242424d2_ex99-1.htm (EX-99.1) — 5KB
• 0001104659-24-003008.txt ( ) — 93KB

(a)

Item 1(a) Name of Issuer: Sera Prognostics, Inc. (the “Issuer”)

(b)

Item 1(b) Address of Issuer’s Principal Executive Offices: 2749 East Parleys Way, Suite 200 Salt Lake City, Utah 84109

(a)

Item 2(a) Name of Person Filing: This Schedule 13G is being filed jointly by the Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Felix J. Baker and Julian C. Baker (collectively, the “Reporting Persons”).

(b)

Item 2(b) Address of Principal Business Office or, if None, Residence: The business address of each of the Reporting Persons is: c/o Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690

(c)

Item 2(c) Citizenship: The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

(d)

Item 2(d) Title of Class of Securities: Class A Common Stock, $0.0001 par value per share (“Common Stock”)

(e)

Item 2(e) CUSIP Number: 81749D107 Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) Bank as defined in section 3(a)(6) of the Exchange Act. (c) Insurance company as defined in section 3(a)(19) of the Exchange Act. (d) Investment company registered under section 8 of the Investment Company Act of 1940. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J). Item 4 Items 5 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock of the Issuer directly held by each of 667, L.P. (“667”) and Baker Brothers Life Sciences, L.P. (“Life Sciences”, and together with 667, the “Funds”), which may be deemed to be indirectly beneficially owned by the Reporting Persons, as well as shares of Common Stock that may be acquired upon the conversion of Class B non-voting common stock of the Issuer (“Class B Common Stock”) (as defined below), subject to the limitations on exercise described below. The information set forth below is based upon 30,368,753 shares of Common Stock outstanding as of November 3, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023. Such percentage figures are calculated in accordance

View Full Filing

View this SC 13G filing on SEC EDGAR